Cartherics has entered a collaborative research agreement with TiCARos, to assess the company's proprietary CLIP-CAR technology in its induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells.
TILT Biotherapeutics, a clinical-stage biotech company developing cancer immunotherapies, has received a $2 million grant from the U.S. Department of Defense (DOD) for a three-year project to treat ovarian cancer using its TILT-123 asset.
Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.
She has a proven track record of leading and mentoring start-ups in the biotechnology field, with her proven abilities in investment and portfolio management, investments, risk management, and business strategy development, Maria is a go-to expert in...
Lonza has launched the Nebula Absorbance Reader, a new absorbance microplate reader, which joins the company’s portfolio of optimized instruments for streamlined endotoxin and pyrogen testing.
Science and technology company Merck has announced the expansion of its facility in Lenexa, Kansas, USA, adding 9,100 sq m2 of lab space and production capability to manufacture cell culture media.
Biotech supply chains face an uncertain future in 2022 and beyond: up against myriad challenges ranging from future pandemic outbreaks to geopolitical tensions – and, indeed, unforeseen threats. Communication and collaboration between policymakers and...
On the eve of Boston Biotech Week, a report was released by MassBio that claimed 48% of all biotech investment in 2017 was accounted for by Massachusetts-based companies.
Biotech M&A started off a bang this year and as the first half of the year has drawn to a close, biotech IPOs have reached a number that could see 2018 become a record-breaker.
Repligen says the single-use version of its alternating tangential flow (ATF) platform is helping the firm capture a larger share of the fed-batch bioreactor marketplace.
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems.
The need for CDMOs with commercial gene therapy capacity is growing says Fujilfilm Diosynth Biotechnologies, which has opened an 80,000 square-foot plant in Texas.
BeiGene’s tislelizumab will be the first commercial product to be made from Boehringer-Ingelheim’s site in Shanghai, and the first to be made by a foreign CMO in China.
Abzena has negotiated the lease on a 50,000 square foot site in San Diego as part of a $17m remodelling of its bioproduction and conjugation facilities.
Pall Corporation has launched a monoclonal antibody clarification platform without centrifugation or process additives to support cell cultures of up to 2,000L.
Following a ¥14bn ($125m) investment in April, Fujifilm Corporation has committed a further ¥3.2bn across its biologics contract manufacturing business.
Pall Corporation will equip WuXi Biologics’ continuous bioprocess laboratory in Shanghai, China, which the latter said would expand process scale and reduce manufacturing costs.
By Cutting the cost of vaccine manufacture, Univercells
High-density single-use bioreactors, small facilities and continuous manufacturing will cut the cost of manufacturing polio vaccines down to $0.15 per dose, says Univercells.
The contract development and manufacturing organisation (CDMO) has selected Pall Life Sciences as its single-use equipment partner at its sites in Florida and Massachusetts.
Lonza has launched an updated version of its cell imaging technology, which it says has improved image capture and data transfer options, and enables researchers to monitor cells remotely.
A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.
A tobacco plant-based platform could make monoclonal antibodies up to 90% cheaper than mammalian systems, says Axis Biotec which is building a pilot plant in Brazil.
Ireland’s “thriving biopharma industry” has traditionally employed large-scale bioreactors, however a new wave of biologics with changing production requirements is changing the trend, say industry representatives.
